Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy

NCT02324998 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Olaparib
DRUG: Degarelix

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Collaborators

[object Object]